Jeffrey Johnson

Title: The Innovative Contributions of Jeffrey Johnson

Introduction

Jeffrey Johnson is a notable inventor based in Summit, NJ (US), recognized for his significant contributions to the field of biotechnology. With a focus on engineering antibodies, he has made strides in developing targeted therapies for cancer treatment.

Latest Patents

Johnson holds a patent for the engineering of an antibody designed for tumor-selective binding of CD47. This innovative antibody comprises at least one Fab portion that binds CD47 and another that binds the tumor-associated antigen (TAA) CD20. The unique design allows the Fab portion that binds CD47 to exhibit low affinity for CD47, while the Fab portion that binds CD20 demonstrates high affinity for CD20. This selective binding mechanism enables the antibody to block CD47 interaction with SIRPα in tumor cells, ensuring minimal binding to CD47 in normal cells.

Career Highlights

Jeffrey Johnson is currently employed at Celgene Corporation, where he continues to advance his research in antibody engineering. His work is pivotal in the development of therapies that could potentially improve cancer treatment outcomes.

Collaborations

Johnson collaborates with esteemed colleagues, including Haralambos Hadjivassiliou and Dan Zhu, who contribute to the innovative research environment at Celgene Corporation.

Conclusion

Jeffrey Johnson's work exemplifies the intersection of innovation and biotechnology, showcasing how targeted therapies can revolutionize cancer treatment. His contributions through patenting novel antibodies highlight the importance of research and collaboration in advancing medical science.